← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Net income increased 37.2% to ($43.4M), while Operating cash flow decreased 85.6% to ($38.4M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($43.4M)Watch
- Cash generation — Free cash flow ($38.6M)Note
- Accounting — No applicable forensic screenNote
- Insiders — 1 buys; 1 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Business
Kalaris Therapeutics, Inc.: ("AlloVir"); and the risk of involvement in litigation, including securities class action litigation, that could divert the attention of our management, harm our business and for which we may not have sufficient insurance coverage to cover all costs and damages.
Leadership changes
From Kalaris Therapeutics, Inc.'s own filings, the day they're filed.
- Matthew Gall · Chief Financial Officer · departureeff. 2026-04-14
- Brett Hagen · Chief Accounting Officer · departureeff. 2026-04-14
- Matthew Gall · Chief Financial Officer · appointmenteff. 2025-11-03
Latest filings
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-11
- 8-K · Company announcement2026-07-20
- 8-K · Company announcement2026-07-17
- 8-K · Company announcement2026-07-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Kalaris Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.